Your critical guide to engage with KAM; enhancing both profitability and customer relations.

Pharma's regulatory landscape and market is changings. Increasing ephasis on efficiency - in terms of both cost and drug effectiveness - means it is paramount that pharma embrace strategic change before 'patent cliffs' are confronted.

The report is business critical for a number of reasons. The successful implementation of KAM creates solid and personal partnerships with longevity in which can lead to consistently high revenues to the detriment of competitors. However, in order to achieve this pharma must work against a number of extremely disruptive elements; namely that KAM does not fit comfortably with the traditional sales model that prioritizes frequency and coverage of doctors' visits.

Pharma Key Account Management 2012 report simplifies these barriers breaking them down into three distinct parts; measurement, value deliver and organization. The outcome being provision of a grounded and practical strategy to move your pharma company forward.

To see exclusive insights from this ground breaking business intelligence report click here now.

The report provides key insights into KAM's...

  • Impact - Find out KAM's commercial effectiveness, patient adherence, sales force numbers and account planning.
  • Value delivery - An analysis of the different selling methods for value proposition, including toolbox versus clean-sheet approach.
  • Success measurement - Learn the shape of what good KAM looks like in pharma and the ways in which it should be measured including; direction, impact, progress, tactic, value and overall results.
  • Organizational challenges - Uncover the key features of the transition to KAM, including the cultural and practical challenges.
  • Future - Understand the power shifts in healthcare, team integration and the benefits of future partnerships as a means to gain greater control in joint working projects assist with compliance and reduce market research.

See now the selected findings PDF!

Featuring Contributions From:

Genzyme

Jeroen Valkenburg
Commercial Effectiveness Manager
Genzyme

Ipsen

Ricardo Castrillo
Business Unit Director
Ipsen Pharma

LEO

Heléna Bargiel
Global Sales Force Excellence Manager
LEO Pharma

Pfizer

Lee Gittings, Dominique Côté,
Martin Parkinson
Pfizer

Roche

Francesco Frattini
Healthcare Development & Access Director
Roche

Astra Zeneca

Chantal Willems
Hospital & Key Account Manager
Astra Zeneca

BMS

Mary Stutts
VP, Global Corporate Communications
Brostol Myers Squibb

Shire

Chris Quinn
Training & Development Manager UK
Shire

Grunthal

Scott Symes
Business Unit Manager
Grunenthal

Janssen Cilag

Simon White
Head of Learning & Development
Janssen

Merck

Ifti Ahmed
Head of Sales Academy, Global Sales Excellence
Merck Serono

Reckitt

Roman Koschuk
Sales Director
Reckitt Benckiser

Astellas Pharma

James Bailey
Regional Business Manager
Astellas Pharma

Bayer

Dr. Mohamed Khater
Head of Marketing & Sales Operations, region EMEA
Bayer Healthcare

Sanofi Aventis

Amy Williams
Senior Product Manager, Diabetes Marketing
Sanofi-Aventis

UCB

Darrell James
Business Analyst
UCB


Peer Reviewed By:

This is a very extensive and informative report which will be invaluable for any pharmaceutical executives looking to implement and embed a key account management culture. It contains some excellent information about virtually every aspect of KAM and it is great to now have a KAM reference that relates totally to pharmaceuticals.

allan_mackintosh
Allan Mackintosh,
PMAP Performance Manager,
Grunenthal UK Ltd.


This eyeforpharma report is valuable for anyone seeking to introduce or improve their KAM strategies. It is a must-read for pharma executives grappling with Key Account Management.

francesco_frattini
Francesco Frattini,
Healthcare Development & Access Director,
Roche, Italy.


This report contains useful information on how to identify & deliver value to customers. It provokes debate and achieves consensus amongst seasoned Key Account Executives, as well as offering insightful, practical advice for those recently adopting KAM. This Eyeforpharma report will play an important role in getting the industry going in the right direction when utilising KAM.

lee_gittings
Lee Gittings,
Regional Accounts Director - Business Effectiveness - Europe & North America,
Pfizer.


This eyeforpharma report has come at an important time for those seeking to benefit from Key Account Management. This report is based on an interesting dialogue which challenged my thinking and made me reflect on how I approached KAM. The information contained will help me improve my strategies and make tangible improvements to my business.

darrell_james
Darrell James,
Business Analyst,
UCB.


Get The Exclusive Report Now
Purchase Now